Add office photos
Engaged Employer
Cipla
4.1
based on 6.6k Reviews
Proud winner of ABECA 2024 - AmbitionBox Employee Choice Awards
Company Overview
Associated Companies
Company Locations
Working at Cipla
Company Summary
Cipla is a leading Global Pharmaceutical Company that ensures access to quality & affordable medicines through various products across various therapeutic categories.
Overall Rating
4.1/5
based on 6.6k reviews
6% above
industry average
Highly rated for
Skill Development, Salary & Benefits, Work-Life Balance
Work Policy
Work from office
71% employees reported
Alternate Saturday off
38% employees reported
Flexible timing
56% employees reported
Within city
39% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
599 employees reported
Health insurance
572 employees reported
Office cab/shuttle
274 employees reported
Professional degree assistance
196 employees reported
View all benefits
About Cipla
Founded in1935 (90 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitecipla.com
Primary Industry
Other Industries
At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades. Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
Report error
AmbitionBox Best Places to Work in India Awards
Best of the best, rated by employees
Cipla won India’s Largest Employee Choice Awards in Large Companies Category.
#2 Top Rated Pharma Company
Share
Cipla Ratings
based on 6.6k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.3k
4
1.8k
3
796
2
282
1
434
Category Ratings
4.0
Skill Development
4.0
Salary & Benefits
3.9
Work-Life Balance
3.9
Company Culture
3.8
Work Satisfaction
3.7
Job Security
3.6
Promotions/Appraisal
Cipla is rated 4.1 out of 5 stars on AmbitionBox, based on 6.6k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Cipla
based on 6.2k reviews
4.1
Rated by 640 Women
Rated 3.9 for Work-Life Balance and 3.9 for Skill Development
4.1
Rated by 5.6k Men
Rated 4.0 for Skill Development and 4.0 for Salary & Benefits
Work Policy at Cipla
based on 578 reviews in last 6 months
Work from office
71%
Hybrid
23%
Permanent work from home
6%
Cipla Reviews
Top mentions in Cipla Reviews
+ 5 more
Compare Cipla with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.6k reviews | 4.2/5 based on 5.8k reviews | 4.0/5 based on 5.6k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Salary & Benefits Work-Life balance | Skill development Company culture Work-Life balance | Salary & Benefits Job Security Skill development | Skill development Work-Life balance Salary & Benefits |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 71% employees reported | Work from office 86% employees reported | Work from office 86% employees reported | - |
Rating by Women Employees | 4.1 Good rated by 640 women | 4.0 Good rated by 343 women | 4.1 Good rated by 410 women | - no rating available |
Rating by Men Employees | 4.1 Good rated by 5.6k men | 4.2 Good rated by 5.2k men | 4.0 Good rated by 4.8k men | - no rating available |
Job Security | 3.7 Good | 3.7 Good | 3.9 Good | 4.0 Good |
View more
Cipla Salaries
4.0
rated by 6.6k employees for salariesDeputy Manager
(1.1k salaries)
Unlock
₹5.3 L/yr - ₹18 L/yr
Area Business Manager
(530 salaries)
Unlock
₹4.4 L/yr - ₹12 L/yr
Therapy Manager
(499 salaries)
Unlock
₹2.4 L/yr - ₹7.1 L/yr
Regional Business Manager
(312 salaries)
Unlock
₹8 L/yr - ₹19 L/yr
Medical Representative
(311 salaries)
Unlock
₹1.9 L/yr - ₹7 L/yr
Production Officer
(235 salaries)
Unlock
₹1.5 L/yr - ₹8 L/yr
Scientific Business Manager
(199 salaries)
Unlock
₹4.1 L/yr - ₹10.8 L/yr
Trainee
(197 salaries)
Unlock
₹1.2 L/yr - ₹4 L/yr
Maintenance Engineer
(195 salaries)
Unlock
₹1.3 L/yr - ₹5 L/yr
Area Sales Manager
(186 salaries)
Unlock
₹4.5 L/yr - ₹11.1 L/yr
Cipla Interview Questions
Interview questions by designation
Top Cipla interview questions and answers
Get interview-ready with top interview questions
Interview Process at Cipla
based on 116 interviews in last 1 year
Interview Experience
4.1
Good
Difficulty level
Easy
19%
Moderate
70%
Hard
11%
People are getting interviews through
based on 331 Cipla interviews
Job Portal
24%
Company Website
18%
Walkin
18%
Referral
16%
*24% candidates got the interview through other sources
High confidence
Cipla Jobs
Cipla News
View all
Markets open lower after strong rally; auto, IT stocks in focus
- Markets open lower after strong rally; auto, IT stocks in focus
- ONGC, Trent, Tata Motors, Titan, and NTPC were the top gainers, while Hero MotoCorp, Tech Mahindra, Cipla, Infosys, and TCS were the top losers.
- The market opened cautiously following a strong rally on Thursday, driven by buying interest in blue-chip stocks.
- Positive market sentiment is attributed to strong December sales data from automakers and optimism ahead of the Union Budget announcement.
HinduBusinessLine | 3 Jan, 2025
Buy, Sell Or Hold: Tata Motors, LIC, SBI, Cipla, Swiggy, NTPC—Ask Profit
- Market analysts share insights for short-term and long-term investors on whether to buy, sell or hold shares of Swiggy, Vishal Mega Mart and Cipla, among others.
- Mazagon Dock Shipbuilders: Chowdhury suggests holding the stock for the long term, while Jain recommends buying shares as they are consolidating.
- Vishal Mega Mart: Chowdhury advises holding the stock for the long term, considering its focus on affordable retailing and expansion plans.
- LIC: Chowdhury advises selling shares and avoiding the insurance sector for now, suggesting HDFC Life as a better option.
Bloomberg Quint | 23 Dec, 2024
Cipla faces penalty of over Rs 1 Cr by GST authorities
- Pharma major Cipla Ltd has been fined over Rs 1 crore by GST authorities for alleged inadmissible credit claim.
- The penalty of Rs 1,11,94,324 has been imposed by the GST authorities under the Central Goods and Services Tax Act.
- Cipla has stated that the penalty is arbitrary and unjustified, and will file necessary appeals with the appellate authority.
- The company has mentioned that there will be no material impact on its financials or operations due to the order.
Yourstory | 20 Dec, 2024
Sensex plunges 964 points as Fed’s hawkish stance sparks market sell-off
- Sensex plunges 964 points as Fed’s hawkish stance sparks market sell-off
- Dr Reddy’s, Cipla, BPCL, Sun Pharma, and Apollo Hospitals emerge as gainers
- Banking and financial services sectors witness significant decline
- Market volatility increases with circuit filters triggered for multiple stocks
HinduBusinessLine | 19 Dec, 2024
Six Stocks In News At Noon: Cipla To Shriram Finance — Top Gainers And Losers
- Cipla, ITC, and Adani Ports were the top gainers in the market at noon.
- Cipla's stock rose by 0.91% following an upgrade by Kotak Securities.
- ITC gained 0.63% after announcing the demerger date for its hotel business.
- Adani Ports saw a gain of 0.58% after achieving a major milestone at its Mundra Port.
- Shriram Finance's stock dropped by 3.92% despite strong demand for its financial services.
Bloomberg Quint | 17 Dec, 2024
Cipla Becomes Top Gainer In Nifty 50 As Kotak Institutional Upgrades To Buy
- Cipla Ltd.'s share price rose to become the top gainer on the NSE Nifty 50 index after Kotak Securities upgraded the stock rating to 'buy'. The brokerage expects recovery in the domestic market and healthy growth in the South African market.
- Kotak Securities reduced the target price but still implied a 19.09% upside from the current closing price. It estimates 9.5% reported earnings per share and compound annual growth rate over FY24 and FY27.
- Cipla stock was impacted by various factors, but Kotak Securities believes most concerns are already factored in the stock price, leading to the upgrade in stock rating.
- Cipla share price rose 2.39% to Rs 1,483.00 apiece and has been rising for three consecutive sessions. Analysts maintain a 'buy' rating on the stock with an average 12-month consensus price target implying a 9.4% upside.
Bloomberg Quint | 17 Dec, 2024
Cipla’s ‘inhaled insulin’ from US’ MannKind Corp adds a ‘layer of convenience’ for those with diabetes
- Cipla has received approval to distribute and market Afrezza, an inhaled insulin, in India.
- Afrezza provides more convenience for individuals with diabetes who are wary of injections.
- The inhaled insulin is not recommended for those with asthma, COPD, and serious lung-related concerns.
- Cipla plans to make Afrezza available by the end of the financial year, pending pricing finalization.
HinduBusinessLine | 12 Dec, 2024
Cipla to bring in inhaled insulin Afreeza from US’ MannKind Corporation
- Cipla has received approval from CDSCO to distribute and market Afrezza, an inhaled insulin powder.
- Afrezza improves glycemic control in adult patients with diabetes mellitus.
- It is the first and only non-injectable insulin for both type 1 and type 2 diabetes mellitus.
- Cipla will partner with MannKind Corporation to supply and distribute Afrezza in India.
HinduBusinessLine | 12 Dec, 2024
Buy, Sell Or Hold: BEL, L&T, Britannia, Voltas, SpiceJet — Ask Profit
- Aditya Arora and Lancelot Dcunha provided expert advice on buying, selling, and holding shares of BEL, L&T, Britannia, Voltas, SpiceJet, Tata Motors, and more on NDTV Profit's Ask Profit show.
- Aditya Arora suggests selling Heritage Foods and holding SpiceJet, while Lancelot Dcunha advises waiting before accumulating Cipla shares.
- Aditya Arora recommends buying Britannia, holding BEL, Voltas, MOIL, and NALCO, and selling Tata Motors on rise.
- Lancelot Dcunha suggests holding L&T and Tata Motors, and adds that Voltas is attempting a breakout.
Bloomberg Quint | 11 Dec, 2024
Cipla to bring in inhaled insulin Afreeza from US’ MannKind Corporation
- The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to distribute and market Afrezza inhalation powder in India.
- Afrezza, developed by MannKind Corporation, is a non-injectable insulin for patients with type 1 and type 2 diabetes mellitus.
- The inhalable insulin starts working in as early as 12 minutes and helps reduce the rapid increase in sugar levels with meals.
- Cipla will distribute Afrezza in India, offering a convenient solution for people uncomfortable with needles.
HinduBusinessLine | 11 Dec, 2024
Powered by
Cipla Subsidiaries
Cipla Health
4.2
• 293 reviews
Report error
Compare Cipla with
Biocon Limited
3.9
Zydus Lifesciences
4.1
Glenmark Pharmaceuticals
4.0
Torrent Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.8
Alkem Laboratories
3.9
Dr. Reddy's
4.1
Viatris
4.2
Abbott
4.2
Alembic Pharmaceuticals
4.0
Ipca Laboratories
4.0
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
Cadila Pharmaceuticals
3.5
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
4.0
Wockhardt
3.9
Piramal Group
3.9
Sanofi
4.3
Contribute & help others!
You can choose to be anonymous
Companies Similar to Cipla
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.6k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 5.8k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.8k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 5.8k reviews
Glenmark Pharmaceuticals
Pharma
4.0
• 2.7k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.4k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.6k reviews
DIVI'S Laboratories
Pharma
3.8
• 1.3k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.8k reviews
Dr. Reddy's
Clinical Research, Pharma
4.1
• 6.6k reviews
Viatris
Manufacturing, Pharma
4.2
• 3k reviews
Cipla FAQs
When was Cipla founded?
Cipla was founded in 1935. The company has been operating for 90 years primarily in the Pharma sector.
Where is the Cipla headquarters located?
Cipla is headquartered in Mumbai, Maharashtra. It operates in 2 cities such as Mumbai, Hyderabad / Secunderabad. To explore all the office locations, visit Cipla locations.
How many employees does Cipla have in India?
Cipla currently has more than 25,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Cipla based on the number of reviews submitted on AmbitionBox.
Does Cipla have good work-life balance?
Cipla has a Work-Life Balance Rating of 3.9 out of 5 based on 6,600+ employee reviews on AmbitionBox. 77% employees rated Cipla 4 or above, while 23% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Cipla work-life balance reviews for more details
Is Cipla good for career growth?
Career growth at Cipla is rated fairly well, with a promotions and appraisal rating of 3.6. 77% employees rated Cipla 4 or above, while 23% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Cipla promotions/appraisals reviews for more detailed insights.
What are the pros of working in Cipla?
Working at Cipla offers several advantages that make it an appealing place for employees. The company is highly rated for skill development, salary & benefits and work life balance, based on 6,600+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
